Evidence map›Paper›PMID 27384989›Full record

ArticleOncotarget2016

Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung.

Roberto Lugo, Marta Gabasa, Francesca Andriani, Marta Puig, Federica Facchinetti, Josep Ramírez, Abel Gómez-Caro, Ugo Pastorino, Gemma Fuster, Isaac Almendros and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Dynamic secretome of bone marrow-derived stromal cells reveals a cardioprotective biochemical cocktail.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  11. Senescent cells: a therapeutic target for cardiovascular disease.The Journal of clinical investigation · 2018
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Roberto LugoUnit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain.
Marta GabasaUnit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain.
Francesca AndrianiTumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Milano, Italy.
Marta PuigUnit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain.
Federica FacchinettiTumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Milano, Italy.
Josep RamírezAnatomopathology Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Abel Gómez-CaroThoracic Surgery Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Ugo PastorinoThoracic Surgery Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Gemma FusterThoracic Surgery Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Isaac AlmendrosUnit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain.
Pere GascónMedical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Albert DavalosBuck Institute for Age Research, Novato, CA, US.
Noemí ReguartMedical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Luca RozTumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Milano, Italy.
Jordi AlcarazUnit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, Spain.
Universitat de Barcelona · ESFondazione IRCCS Istituto Nazionale dei Tumori · ITHospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESBuck Institute for Research on Aging · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Senescence in cancer cells acts as a tumor suppressor, whereas in fibroblasts enhances tumor growth. Senescence has been reported in tumor associated fibroblasts (TAFs) from a growing list of cancer subtypes. However, the presence of senescent TAFs in lung cancer remains undefined. We examined senescence in TAFs from primary lung cancer and paired control fibroblasts from unaffected tissue in three major histologic subtypes: adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). Three independent senescence markers (senescence-associated beta-galactosidase, permanent growth arrest and spreading) were consistently observed in cultured LCC-TAFs only, revealing a selective premature senescence. Intriguingly, SCC-TAFs exhibited a poor growth response in the absence of senescence markers, indicating a dysfunctional phenotype rather than senescence. Co-culturing normal fibroblasts with LCC (but not ADC or SCC) cancer cells was sufficient to render fibroblasts senescent through oxidative stress, indicating that senescence in LCC-TAFs is driven by heterotypic signaling. In addition, senescent fibroblasts provided selective growth and invasive advantages to LCC cells in culture compared to normal fibroblasts. Likewise, senescent fibroblasts enhanced tumor growth and lung dissemination of tumor cells when co-injected with LCC cells in nude mice beyond the effects induced by control fibroblasts. These results define the subtype-specific aberrant phenotypes of lung TAFs, thereby challenging the common assumption that lung TAFs are a heterogeneous myofibroblast-like cell population regardless of their subtype. Importantly, because LCC often distinguishes itself in the clinic by its aggressive nature, we argue that senescent TAFs may contribute to the selective aggressive behavior of LCC tumors.

Indexed as

Cellular SenescenceParacrine CommunicationAnimalsbeta-GalactosidaseCancer-Associated FibroblastsCarcinoma, Large CellCell Cycle CheckpointsCell Line, TumorCell MovementCell ShapeCoculture TechniquesCulture Media, ConditionedDisease ProgressionFemaleHumansLung Neoplasmsbeta-GalactosidaseCulture Media, Conditionedcancer associated fibroblastinvasionlarge cell carcinomalung cancersenescence

Identifiers

PMID27384989
PMCPMC5347694
OpenAlexW2474099256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.